Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $1.9 million.

  • Lipocine's Total Liabilities rose 2212.86% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 2212.86%. This contributed to the annual value of $1.5 million for FY2024, which is 4250.95% down from last year.
  • Lipocine's Total Liabilities amounted to $1.9 million in Q3 2025, which was up 2212.86% from $1.4 million recorded in Q2 2025.
  • Lipocine's Total Liabilities' 5-year high stood at $11.4 million during Q2 2021, with a 5-year trough of $1.3 million in Q1 2025.
  • Moreover, its 5-year median value for Total Liabilities was $1.9 million (2023), whereas its average is $3.4 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 7985.22% in 2022, then soared by 3792.73% in 2023.
  • Quarter analysis of 5 years shows Lipocine's Total Liabilities stood at $6.9 million in 2021, then tumbled by 72.4% to $1.9 million in 2022, then skyrocketed by 37.93% to $2.6 million in 2023, then tumbled by 42.51% to $1.5 million in 2024, then grew by 27.64% to $1.9 million in 2025.
  • Its Total Liabilities stands at $1.9 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.3 million for Q1 2025.